Difference between revisions of "Tosedostat (CHR-2797)"
Jump to navigation
Jump to search
(Created page with "=Preliminary Results= ==Phase II== # Jorge Cortes, Eric Feldman, Karen Yee, David Rizzieri, Anjali S Advani, Anthony Charman, Richard Spruyt, Martin Toal, Hagop Kantarjian, T...") |
m (→Phase II) |
||
| Line 2: | Line 2: | ||
==Phase II== | ==Phase II== | ||
| − | # Jorge Cortes, Eric Feldman, Karen Yee, David Rizzieri, Anjali S Advani, Anthony Charman, Richard Spruyt, Martin Toal, Hagop Kantarjian, Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study, The Lancet Oncology, Volume 14, Issue 4, April 2013, Pages 354-362, ISSN 1470-2045, 10.1016/S1470-2045(13)70037-8. | + | # Jorge Cortes, Eric Feldman, Karen Yee, David Rizzieri, Anjali S Advani, Anthony Charman, Richard Spruyt, Martin Toal, Hagop Kantarjian, Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study, The Lancet Oncology, Volume 14, Issue 4, April 2013, Pages 354-362, ISSN 1470-2045, 10.1016/S1470-2045(13)70037-8. [http://www.sciencedirect.com/science/article/pii/S1470204513700378 link to article] |
| − | [http://www.sciencedirect.com/science/article/pii/S1470204513700378 link to article] | ||
Revision as of 16:17, 4 April 2013
Preliminary Results
Phase II
- Jorge Cortes, Eric Feldman, Karen Yee, David Rizzieri, Anjali S Advani, Anthony Charman, Richard Spruyt, Martin Toal, Hagop Kantarjian, Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study, The Lancet Oncology, Volume 14, Issue 4, April 2013, Pages 354-362, ISSN 1470-2045, 10.1016/S1470-2045(13)70037-8. link to article